Polycystic Kidney Disease Treatment Market

1. Executive Summary
    1.1. Key Market Insights  

2. Introduction            
    2.1. Study Objectives        
    2.2. Market Definition        
           2.2.1. Market Covered    
           2.2.2. Regional Coverage    
           2.2.3. Study Years & Currency    
    2.3. Market Stakeholders        
    2.4. Key Questions this Study will Answer        
    2.5. GMI Research’s Approach & Methodology  
           2.5.1. Research Data
           2.5.2. Primary Data
           2.5.3. Demand Side and Supply Side Analysis
           2.5.4. Market Size Estimation
           2.5.5. Research Assumptions

3. Global Polycystic Kidney Disease Treatment Market- Overview            
    3.1. Introduction         
    3.2. Market Segmentation        
    3.3. Value Chain Analysis        
    3.4. Market Drivers        
    3.5. Market Restraints        
    3.6. Market Trends      

4. Global Polycystic Kidney Disease Treatment Market Revenue Forecast till 2028     

5. Global Polycystic Kidney Disease Treatment Market by Type Revenue Forecast till 2028            
    5.1. Autosomal dominant polycystic kidney disease (ADPKD)
    5.2. Autosomal recessive polycystic kidney disease (ARPKD)

6. Global Polycystic Kidney Disease Treatment Market by Test Type Revenue Forecast till 2028            
    6.1. Urine Test
    6.2. Blood Test
    6.3. Imaging Test
    6.4. Others

7. Global Polycystic Kidney Disease Treatment Market by Treatment Type Revenue Forecast till 2028            
    7.1. Therapy
    7.2. Drugs

8. Global Polycystic Kidney Disease Treatment Market by Region Forecast till 2028
    8.1. North America Polycystic Kidney Disease Treatment Market Revenue Forecast till 2028 
    (Option 1: As a part of the free 25% customization)
           8.1.1. North America Polycystic Kidney Disease Treatment Market by Type
                     8.1.1.1. Autosomal dominant polycystic kidney disease (ADPKD)
                     8.1.1.2. Autosomal recessive polycystic kidney disease (ARPKD)
           8.1.2. North America Polycystic Kidney Disease Treatment Market by Test Type
                     8.1.2.1. Urine Test
                     8.1.2.2. Blood Test
                     8.1.2.3. Imaging Test
                     8.1.2.4. Others 
           8.1.3. North America Polycystic Kidney Disease Treatment Market by Treatment Type
                     8.1.3.1. Therapy
                     8.1.3.2. Drugs
           8.1.4. US Polycystic Kidney Disease Treatment Market All-Up
           8.1.5. Canada Polycystic Kidney Disease Treatment Market All-Up
    8.2. Europe Polycystic Kidney Disease Treatment Market Revenue Forecast till 2028 
    (Option 2: As a part of the free 25% customization)
           8.2.1. Europe Polycystic Kidney Disease Treatment Market by Type
                     8.2.1.1. Autosomal dominant polycystic kidney disease (ADPKD)
                     8.2.1.2. Autosomal recessive polycystic kidney disease (ARPKD)
           8.2.2. Europe Polycystic Kidney Disease Treatment Market by Test Type
                     8.2.2.1. Urine Test
                     8.2.2.2. Blood Test
                     8.2.2.3. Imaging Test
                     8.2.2.4. Others 
           8.2.3. Europe Polycystic Kidney Disease Treatment Market by Treatment Type
                     8.2.3.1. Therapy
                     8.2.3.2. Drugs
           8.2.4. UK Polycystic Kidney Disease Treatment Market All-Up
           8.2.5. Germany Polycystic Kidney Disease Treatment Market All-Up
           8.2.6. France Polycystic Kidney Disease Treatment Market All-Up
           8.2.7. Spain Polycystic Kidney Disease Treatment Market All-Up
           8.2.8. Rest of Europe Polycystic Kidney Disease Treatment Market All-Up
    8.3. Asia-Pacific Polycystic Kidney Disease Treatment Market Revenue Forecast till 2028 
    (Option 3: As a part of the free 25% customization) 
           8.3.1. Asia-Pacific Polycystic Kidney Disease Treatment Market by Type
                     8.3.1.1. Autosomal dominant polycystic kidney disease (ADPKD)
                     8.3.1.2. Autosomal recessive polycystic kidney disease (ARPKD)
           8.3.2. Asia-Pacific Polycystic Kidney Disease Treatment Market by Test Type
                     8.3.2.1. Urine Test
                     8.3.2.2. Blood Test
                     8.3.2.3. Imaging Test
                     8.3.2.4. Others 
           8.3.3. Asia-Pacific Polycystic Kidney Disease Treatment Market by Treatment Type
                     8.3.3.1. Therapy
                     8.3.3.2. Drugs
           8.3.4. China Polycystic Kidney Disease Treatment Market All-Up
           8.3.5. India Polycystic Kidney Disease Treatment Market All-Up
           8.3.6. Japan Polycystic Kidney Disease Treatment Market All-Up
           8.3.7. Rest of APAC Polycystic Kidney Disease Treatment Market All-Up
    8.4. RoW Polycystic Kidney Disease Treatment Market Revenue Forecast till 2028
    (Option 4: As a part of the free 25% customization)  
           8.4.1. RoW Polycystic Kidney Disease Treatment Market by Type
                     8.4.1.1. Autosomal dominant polycystic kidney disease (ADPKD)
                     8.4.1.2. Autosomal recessive polycystic kidney disease (ARPKD)
           8.4.2. RoW Polycystic Kidney Disease Treatment Market by Test Type
                     8.4.2.1. Urine Test
                     8.4.2.2. Blood Test
                     8.4.2.3. Imaging Test
                     8.4.2.4. Others 
           8.4.3. RoW Polycystic Kidney Disease Treatment Market by Treatment Type
                     8.4.3.1. Therapy
                     8.4.3.2. Drugs
           8.4.4. Brazil Polycystic Kidney Disease Treatment Market All-Up
           8.4.5. South Africa Polycystic Kidney Disease Treatment Market All-Up
           8.4.6. Saudi Arabia Polycystic Kidney Disease Treatment Market All-Up
           8.4.7. UAE Polycystic Kidney Disease Treatment Market All-Up
           8.4.8. Rest of world (remaining countries of the LAMEA region) Polycystic Kidney Disease Treatment Market All-Up

9. Competitive Landscape Analysis
    9.1. Porter’s Five Forces Analysis
    9.2. Industry – Competitive Landscape
    9.3. Market Presence (Intensity Mapping)
    9.4. Key Strategic Market Developments 

10. Company Profiles (Option 5: Free 25% Customization - Profiles of 5 Additional Companies of your Choice)
    10.1. Otsuka Holdings Co., Ltd.
           10.1.1. Company Overview    
           10.1.2. Key Executives 
           10.1.3. Footprint & Employee Strength 
           10.1.4. Product Offerings    
           10.1.5. Financials
           10.1.6. Key Company Developments 
    10.2. Exelixis, Inc.
           10.2.1. Company Overview    
           10.2.2. Key Executives   
           10.2.3. Footprint & Employee Strength
           10.2.4. Product Offerings
           10.2.5. Financials
           10.2.6. Key Company Developments
    10.3. CELGENE CORPORATION
           10.3.1. Company Overview    
           10.3.2. Key Executives
           10.3.3. Footprint & Employee Strength
           10.3.4. Product Offerings
           10.3.5. Financials
           10.3.6. Key Company Developments
    10.4. XORTX Therapeutics Inc.
           10.4.1. Company Overview    
           10.4.2. Key Executives
           10.4.3. Footprint & Employee Strength
           10.4.4. Product Offerings
           10.4.5. Financials
           10.4.6. Key Company Developments
    10.5. ManRos Therapeutics
           10.5.1. Company Overview    
           10.5.2. Key Executives   
           10.5.3. Footprint & Employee Strength
           10.5.4. Product Offerings
           10.5.5. Financials
           10.5.6. Key Company Developments
    10.6. Palladio Biosciences
           10.6.1. Company Overview    
           10.6.2. Key Executives
           10.6.3. Footprint & Employee Strength
           10.6.4. Product Offerings
           10.6.5. Financials
           10.6.6. Key Company Developments
    10.7. Regulus Therapeutics Inc.
           10.7.1. Company Overview
           10.7.2. Key Executives
           10.7.3. Footprint & Employee Strength
           10.7.4. Product Offerings
           10.7.5. Financials
           10.7.6. Key Company Developments    
    10.8. Kadmon Holdings, Inc.
           10.8.1. Company Overview
           10.8.2. Key Executives 
           10.8.3. Footprint & Employee Strength
           10.8.4. Product Offerings
           10.8.5. Financials
           10.8.6. Key Company Developments    
    10.9. Reata Pharmaceuticals, Inc.
           10.9.1. Company Overview
           10.9.2. Key Executives 
           10.9.3. Footprint & Employee Strength
           10.9.4. Product Offerings
           10.9.5. Financials
           10.9.6. Key Company Developments   
    10.10. NovaTarg Therapeutics
           10.10.1. Company Overview
           10.10.2. Key Executives 
           10.10.3. Footprint & Employee Strength
           10.10.4. Product Offerings
           10.10.5. Financials
           10.10.6. Key Company Developments   

11. About GMI Research

*Details on Financials might not be available in case of unlisted/private companies.

*The list of companies is based on preliminary research in this sample report, the companies in the final report may change based on research findings.